Researchers at the University of Copenhagen have identified a new drug target for weight loss that curbs appetite, boosts energy use, and enhances insulin sensitivity without causing nausea or muscle loss. This discovery may pave the way for effective treatments for obesity and type 2 diabetes. Millions worldwide benefit from weight loss drugs derived from the incretin hormone GLP-1. These medications not only aid in weight management but also enhance kidney function, lower the risk of fatal cardiac events, and show potential in protecting against neurodegeneration. However, many individuals discontinue these medications due to common side effects such as nausea...